Kyi Yu
Family Medicine · Rockaway Beach, NYNPI 1427095686
Payments from drug & device makers
Across 429 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$973
- AstraZeneca$803
- Otsuka America Pharmaceutical, Inc.$702
- Lilly USA, LLC$485
- Boehringer Ingelheim$484
- Cumberland Pharmaceuticals, Inc.$480
- plus $4K from 45 others
What the payments were for
- Food & beverage$8,343100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$125
- DUPIXENT$125
How this compares
$8,362 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 509 | $490,779 |
| JardianceEmpagliflozin | 497 | $341,639 |
| JanuviaSitagliptin Phosphate | 307 | $232,146 |
| MounjaroTirzepatide | 224 | $228,716 |
| TrulicityDulaglutide | 206 | $206,656 |
| EliquisApixaban | 298 | $192,246 |
| Metformin Er GastricMetformin Hcl | 86 | $187,595 |
| Diclofenac Sodium | 408 | $170,967 |
| FarxigaDapagliflozin Propanediol | 191 | $117,385 |
| LinzessLinaclotide | 216 | $113,775 |
| RybelsusSemaglutide | 95 | $100,867 |
| JanumetSitagliptin Phos/Metformin Hcl | 146 | $90,580 |
| XareltoRivaroxaban | 103 | $89,426 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 131 | $88,317 |
| Humira(Cf) PenAdalimumab | 11 | $79,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $485 | $435,373430 claims |
| Boehringer IngelheimJardiance, Tradjenta | $484 | $388,446574 claims |
| MerckJanuvia, Janumet | $228 | $322,726453 claims |
| PfizerEliquis | $109 | $192,246298 claims |
| AbbVieLinzess, Namzaric, Synthroid | $973 | $162,180509 claims |
| AstraZenecaFarxiga | $803 | $117,385191 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $307 | $112,767186 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $38 | $104,668117 claims |
| AmgenProlia | $120 | $74,86246 claims |
| NovartisEntresto | $72 | $72,442100 claims |
| Smith+NephewSantyl | $74 | $48,07227 claims |
| Astellas Pharma US IncMyrbetriq | $109 | $18,70641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Rockaway Beach
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.